Bruce Rogers

Bruce Rogers

Company: Morphic Therapeutics

Job title: President


MORF-057 – A selective oral α4B7 Integrin Inhibitor for Inflammatory Bowel Disease 11:30 am

α4B7 Integrin inhibition is a clinically validated mechanism of action to treat IBD Utilizing the MInT platform, we have identified the highly selective oral Inhibitor MORF-057 and advanced it into clinical studies Phase 1 clinical data support the initiation of Phase 2 clinical trials in UCRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.